HCC

In an interview with Targeted Oncology Richard Finn, MD, discussed the implications of the LEAP-002 trial.

In an interview with Targeted Oncology, Pierre Gholam, MD, discussed multiple studies currently influencing the hepatocellular carcinoma treatment landscape.

At the 2022 ESMO Congress, results from the final analysis of the RATIONALE-301 study showed that tislelizumab monotherapy continued to have clinically meaningful anti-tumor activity vs sorafenib in patients with unresectable hepatocellular carcinoma.

Although the combination use of lenvatinib plus pembrolizumab did not induce statistically significant differences in the co-primary end points, the LEAP-002 trial induced the longest seen median overall survival with lenvatinib monotherapy in patients with unresectable HCC.

Findings presented at ESMO 2022 show the survival benefits of camrelizumab plus rivoceranib in patients with unresectable HCC.

Mark Yarchoan, MD, discusses the current hepatocellular carcinoma space as well as 3 late breaking abstracts that will be presented at the 2022 ESMO Congress.

Daneng Li, MD, discusses potential second-line options following treatment with bevacizumab plus atezolizumab in patients with hepatocellular carcinoma.

During a Targeted Oncology case-based roundtable event, Ghassan K. Abou-Alfa, MD, MBA, discussed the case of a patient with hepatocellular carcinoma whose comorbidities impacted the choice of treatment.

The phase 3 RATIONALE 301 trial of tislelizumab in patients with unresectable hepatocellular carcinoma has met its primary end point of non-inferior overall survival.

Arndt Vogel, MD, discusses the study results of the IMMUTACE study in hepatocellular carcinoma.

While treatment with pembrolizumab and lenvatinib vs lenvatinib alone seemed to have survival benefit in patients with unresectable hepatocellular carcinoma, the primary end points of the trial were missed.

Ghassan K. Abou-Alfa, MD,discusses the phase 2 study of tislelizumab in patients with unresectable hepatocellular carcinoma.

According to Lorenza Di Marco, PhD, immunotherapy treatment can increase the risk of liver rejection in patients with recurrent HCC who have undergone a liver transplant.

Expert panelists consider later-line treatment options for a patient with recurrent hepatocellular carcinoma.

Comprehensive insight on several clinical trials analyzing frontline combination therapies for patients with unresectable hepatocellular carcinoma.

A presentation by Richard S. Finn, MD, during the American Association for Cancer Research Special Conference, focused on phase 3 combination studies in that setting.

The superiority of the combination regimens for hepatocellular carcinoma treatment was demonstrated in results from the IMbrave150 and HIMALAYA trials, according to Josep M. Llovet, MD, PhD.

In COSMIC-312, reduction in the risk of disease progression or death was achieved with the combination of cabozantinib Plus atezolizumab compatient with sorafenib in patient with hepatocellular carcinoma.

During a Targeted Oncology case-based roundtable event, Ghassan K. Abou-Alfa, MD, discussed therapeutic sequencing for patients with unresectable hepatocellular carcinoma and the use of lenvatinib versus sorafenib.

Improvement in overall survival has been demonstrated with the combination of durvalumab and tremelimumab in patients with unresectable liver cancer treated in the phase 3 HIMALAYA study.

During a live virtual event, Daneng Li, MD, discussed the case of a 77-year-old woman with stage IV hepatocellular cancer and a Child-Pugh score of A. This is the first of 2 articles from this event.

Sharing the first patient case of unresectable hepatocellular carcinoma, experts consider optimal screening and diagnosis practices in this setting.

During a Targeted Oncology case-based roundtable event, Richard S. Finn, MD, discussed the case of a patient with hepatocellular cancer with a medical history of Crohn disease, cirrhosis, and variceal bleeding.

Amaia Lujambio Goizueta, PhD, discusses the unanswered questions currently circulating the hepatocellular carcinoma field.

Amaia Lujambio Goizueta, PhD, discusses a new approach to overcoming resistance to immunotherapy for patients with hepatocellular carcinoma.